STERIS (STE) Projected to Post Earnings on Wednesday

STERIS (NYSE:STE) is expected to be announcing its Q2 2027 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of $2.67 per share and revenue of $1.56 billion for the quarter. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. Individuals can find conference call details on the company’s upcoming Q2 2027 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:00 AM ET.

STERIS (NYSE:STE) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.10. The company had revenue of $1.49 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $2.34 earnings per share. The firm’s quarterly revenue was up 7.3% compared to the same quarter last year. On average, analysts expect STERIS to post $11.17 EPS for the current fiscal year and $12.40 EPS for the next fiscal year.

STERIS Trading Down 0.6%

Shares of NYSE STE opened at $227.06 on Wednesday. STERIS has a twelve month low of $195.14 and a twelve month high of $269.44. The firm has a 50-day moving average of $220.16 and a two-hundred day moving average of $225.65. The company has a market capitalization of $22.14 billion, a price-to-earnings ratio of 27.89 and a beta of 0.92.

STERIS Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 25th. Investors of record on Friday, September 4th were issued a dividend of $0.69 per share. This is a positive change from STERIS’s previous quarterly dividend of $0.63. This represents a $2.76 annualized dividend and a dividend yield of 1.2%. The ex-dividend date was Friday, September 4th. STERIS’s dividend payout ratio is 33.74%.

Insiders Place Their Bets

In related news, Director Mohsen Sohi sold 4,058 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $235.78, for a total transaction of $956,795.24. Following the completion of the sale, the director owned 24,305 shares of the company’s stock, valued at $5,730,632.90. This represents a 14.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 1.12% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. UBS Group reduced their target price on STERIS from $275.00 to $270.00 and set a “buy” rating for the company in a report on Friday, August 7th. Wall Street Zen downgraded STERIS from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 11th. Weiss Ratings restated a “hold (c)” rating on shares of STERIS in a research report on Monday, August 24th. Finally, Piper Sandler reissued an “overweight” rating and issued a $275.00 target price (up from $270.00) on shares of STERIS in a research note on Friday, August 7th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, STERIS has a consensus rating of “Moderate Buy” and an average price target of $271.33.

About STERIS

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, procedural care and the safe manufacture of healthcare and life sciences products. Its offerings include surgical equipment and operating-room solutions, sterilization and decontamination systems, endoscopy products, cleaning and disinfection technologies, and related consumable products.

The company also provides outsourced sterilization and laboratory services through its Applied Sterilization Technologies business.